



Recommendations for Prevention and Control of Influenza in Children, 2025–2026: Policy Statement

Committee on Infectious Diseases

abstract

Address correspondence to: Kristina A. Bryant, MD, FAAP. k0brya01@louisville.edu

CONFLICT OF INTEREST DISCLOSURE: Dr Bryant has no disclosed conflicts related to the content of this statement. Dr Bryant has disclosed completed or ongoing research relationships with Gilead, Pfizer, Sanofi, and Enanta that were reviewed and determined not relevant to influenza. Dr Bryant receives honoraria from WebMed, a stipend from the American Society of Nephrology, and royalties from Oxford University Press. Committee on Infectious Diseases members who disclosed relevant conflicts did not participate in the development of this statement.

FUNDING: No external funding.

This document is copyrighted and is property of the American Academy of Pediatrics and its Board of Directors. All authors have filed conflict of interest statements with the American Academy of Pediatrics. Any conflicts have been resolved through a process approved by the Board of Directors. The American Academy of Pediatrics has neither solicited nor accepted any commercial involvement in the development of the content of this publication.

Policy statements from the American Academy of Pediatrics benefit from expertise and resources of liaisons and internal (AAP) and external reviewers. However, policy statements from the American Academy of Pediatrics may not reflect the views of the liaisons or the organizations or government agencies that they represent.

The guidance in this statement does not indicate an exclusive course of treatment or serve as a standard of medical care. Variations, taking into account individual circumstances, may be appropriate.

To cite: American Academy of Pediatrics, Committee on Infectious Diseases. Recommendations for Prevention and Control of Influenza in Children, 2025–2026: Policy Statement. *Pediatrics*. 2025;156(6):e2025073620

This statement updates the recommendations of the American Academy of Pediatrics (AAP) for the use of influenza vaccines and antiviral medications in the prevention and treatment of influenza in children during the 2025–2026 influenza season. A review of the evidence supporting these recommendations is in the accompanying technical report (<https://doi.org/10.1542/peds.2025-073622>).

The AAP recommends annual influenza vaccination of all children without medical contraindications starting at 6 months of age. Influenza vaccination is an important strategy for protecting children and the broader community as well as reducing the overall burden of respiratory illnesses when other viruses are cocirculating. Any licensed influenza vaccine appropriate for age and health status can be administered, as soon as possible in the season, without preference for one product or formulation.

Antiviral treatment of influenza is recommended for children with suspected or confirmed influenza who are hospitalized or have severe or progressive disease or have underlying conditions that increase their risk of complications of influenza. In this situation, antiviral treatment should be started as soon as possible regardless of duration of illness. Antiviral treatment is an option in the outpatient setting for other children with suspected or confirmed influenza in some circumstances.

Antiviral chemoprophylaxis is an option in certain individuals, especially exposed children who are asymptomatic and are at high risk for influenza complications but have not yet been immunized or those who are not expected to mount an effective immune response.

INTRODUCTION

Children, especially those younger than 5 years and those with certain underlying medical conditions, can experience substantial morbidity, including severe or fatal complications, from influenza virus infection.^{1–3} Children also play a pivotal role in the transmission of influenza virus infection to household and other close contacts.^{4–6}

Influenza vaccination of children can reduce disease burden directly and among household members, close contacts, and community members of all ages.^{7,8} By reducing the burden of respiratory illnesses, influenza vaccination helps to preserve health care capacity, especially when other viruses are cocirculating. The American Academy of Pediatrics (AAP) recommends routine influenza vaccination of children ≥6 months of age for the prevention of influenza. Despite this recommendation, influenza vaccination coverage decreased again during the 2024–2025 influenza season. Through April 26, 2025, only 49.2% of children 6 months through 17 years had been vaccinated, 14.5 percentage points lower than at the end of 2020 (<https://www.cdc.gov/fluview/interactive/general-population-coverage.html>). Differences in vaccination rates were noted by age, race, and ethnicity; poverty status; urbanicity; and maternal immunization status.⁹ Continued efforts to increase influenza vaccination, including strategies to decrease disparities in vaccine access and delivery and to counter vaccine hesitancy, are urgently needed.

This policy statement summarizes updates and recommendations for the 2025–2026 influenza season. An accompanying technical report provides further detail.¹⁰

UPDATES FOR THE 2025–2026 INFLUENZA SEASON

1. All licensed vaccines available in the United States this season are trivalent.
2. The compositions of influenza vaccines for the 2025–2026 season have been updated (Table 1).
3. Recommendations for influenza treatment and prophylaxis have been simplified.
4. Live attenuated influenza vaccine (LAIV) is available for administration in the home by a caregiver for eligible children ≥2 years of age.
5. Recombinant baculovirus-expressed hemagglutinin (HA) influenza vaccine (RIV3) is now licensed for individuals as young as 9 years of age.¹¹

HIGH-RISK GROUPS IN PEDIATRICS

Children younger than 5 years, especially those younger than 2 years, and children with certain underlying medical conditions are at increased risk of hospitalization and complications attributable to influenza (Table 2).¹⁰ Although influenza vaccination is recommended for everyone starting at 6 months of age, emphasis should be placed on ensuring that high-risk children, medically vulnerable

TABLE 1. Trivalent Influenza Vaccine Composition for the 2025–2026 Season	
	Specific Strain
Influenza A	
H1N1	A/Victoria/4897/2022 (H1N1)pdm09-like virus (egg-based) ^a
	A/Wisconsin/67/2022 (H1N1)pdm09-like virus (cell culture-based or recombinant) ^a
H3N2	A/Croatia/10136RV/2023 (H3N2)-like virus (egg-based) ^b
	A/District of Columbia/27/2023 (H3N2)-like virus (cell culture-based or recombinant) ^b
Influenza B	
Victoria	B/Austria/1359417/2021-like virus (B/Victoria lineage) ^a
Quadrivalent vaccines are still available outside the United States.	
^a Unchanged this season.	
^b New this season.	

children, and children with medical complexity, as well as their parents/guardians, other household contacts, and caregivers, receive annual influenza vaccine (Table 3). Additionally, increased efforts are needed to eliminate barriers to vaccination in all persons experiencing higher rates of adverse outcomes from influenza. Racial and ethnic disparities exist in severe outcomes from influenza, with some group experiencing higher rates of severe outcomes.¹² In 1 cross-sectional study spanning 10 influenza seasons, Black, Hispanic, and American Indian/Alaska Native people had higher rates of influenza-associated hospitalizations and intensive care unit admissions, and disparities were highest in children ≤4 years of age.¹² Influenza-associated in-hospital deaths were three- to 4-fold higher in Black, Hispanic, and Asian/Pacific Islander children compared with white children.¹² Inequities in health care system access and other social drivers of health contribute to severe outcomes and increased mortality in these groups.

SEASONAL INFLUENZA VACCINES

The seasonal influenza vaccines licensed for children for the 2025–2026 season are described in Table 4. As in the 2024–2025 season, all 2025–2026 seasonal influenza vaccines available in the United States are trivalent and contain hemagglutinin derived from the same influenza strains as recommended by the World Health Organization (WHO) and the US Food and Drug Administration (FDA) for the Northern Hemisphere (Table 1).^{13,14} The influenza A (H3N2) vaccine component for the 2025–2026 season has been updated. The influenza A (H1N1) and influenza B Victoria lineage are unchanged.

INFLUENZA VACCINE RECOMMENDATIONS

General Recommendations

1. The AAP recommends influenza vaccination of everyone 6 months and older during the 2025–2026 influenza season.

TABLE 2. High-Risk Groups for Influenza Complications	
Category	Description
Demographic Characteristics	Children <5 y, especially those <2 y ^a
	Children born preterm or early term ^b
	Residents of a chronic care facility or nursing home
Underlying Condition or Treatment with Common Examples ^c	
Chronic pulmonary disease	Asthma ²¹
	Cystic fibrosis Bronchopulmonary dysplasia ²¹
	Compromised respiratory function (eg, requiring mechanical ventilation, tracheostomy)
Cardiovascular disease	Hemodynamically significant conditions (excluding hypertension alone)
Kidney disease	Chronic kidney disease, including end-stage kidney disease Dialysis
Hepatic disease	Chronic liver disease Cirrhosis ^{22,23}
Hematologic disease	Sickle cell disease
	Other hemoglobinopathies
Metabolic disorders	Diabetes mellitus
Neurologic and neurodevelopmental conditions	Cerebral palsy
	Epilepsy
	Stroke
	Intellectual developmental disorder
	Moderate to severe developmental delay
	Neuromuscular disorders, including muscular dystrophy
	Spinal cord injury
Extreme obesity	BMI ≥40 for adults; BMI ≥the 95th percentile in children ^d
Immunosuppression	Receipt of immunocompromising medications
	Receipt of hematopoietic cell transplant or solid organ transplant
	Congenital or acquired immune deficiency, including HIV
	Asplenia
Receiving treatment with aspirin or salicylate-containing therapies ^e	
Pregnancy and up to 2 weeks postpartum	
Abbreviation: BMI, body mass index. ^a Regardless of the presence of underlying medical conditions. ^b Higher risk of influenza hospitalization in the first 5 years of life. ^c List of examples is not exhaustive. ^d BMI associated with increased risk not well-defined in children but could consider BMI at or above the 95th percentile for children and adolescents of the same age and sex. ^{24,25} ^e Applies to children and adolescents <19 years who may be at increased risk of Reye syndrome. Grohskopf LA, Ferdinands JM, Blanton LH, Broder KR, Loehr J. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2024–25 influenza season. <i>MMWR Recomm Rep</i> . 2024;73(RR-5):1–25.	

TABLE 3. Strategies for Increasing Childhood Influenza Vaccination	
Clinician/Care Team	
- Offer strong, presumptive influenza vaccine recommendation - Bundle recommendation for influenza vaccine with recommendations for other needed vaccines - Use consistent messaging across care team members - Identify influenza vaccine champion(s)	
Practice/Health System	
- Review influenza vaccination status at all visits - Bundle influenza vaccine with other needed vaccines - Vaccinate at all visit types (eg, well child, acute care visits) - Vaccinate in all health care settings (eg, hospital, emergency department, subspecialty practice) - Increase access to influenza vaccine (eg, expanded hours, vaccine-only clinic) - Provide evidence-based information to patients and families (eg, office-based educational handout) - Offer scripting for staff and messaging for patients and families to address common questions, including frequent misconceptions and relevant contraindications and precautions, including allergies - Consider an early or expedited allergy referral for patients with a potential flu vaccine allergy to ensure timely vaccination when appropriate - Send influenza vaccine reminder/recall messages - Use electronic health record (EHR)-based tools to identify and classify high-risk patients for targeted outreach - Utilize standing orders for influenza vaccine - Implement influenza vaccine prompts/clinical decision support - Perform audits and share feedback reports	
Community/Public Health	
- Integrate electronic health record with regional or state immunization information system (IIS) and automate reconciliation of electronically received influenza vaccine administration data - Partner with stakeholders to support vaccine initiatives within the community, including school-based programs and pharmacies - Engage with communities affected by health disparities to develop tailored strategies that promote trust, encourage dialogue, and increase access to preventive services	

- The AAP recommends any licensed influenza vaccine product appropriate for age and health status and does not prefer one product over another, including inactivated (non-live) influenza vaccine (IIV) or recombinant influenza vaccine (RIV) and LAIV. RIV is now an option for persons ≥9 years of age.¹¹ Influenza vaccination should not be delayed to obtain a specific product, including a thimerosal-free product. The safety of thimerosal-containing vaccines is discussed in the technical report in the section "Safety of IIV and RIV" (<https://doi.org/10.1542/peds.2025-073622>).
- LAIV should not be used for immunocompromised persons and persons with certain chronic medical conditions (Table 5).
- The number of influenza vaccine doses recommended for children remains unchanged in the 2025–2026 influenza season and depends on the child's age at first

TABLE 4. Recommended Seasonal Influenza Vaccines for Children and Adolescents: United States, 2025–2026 Influenza Season					
Vaccine	Trade Name (Manufacturer)	Age Group	Presentation and Hemagglutinin Antigen Content (IIVs and RIV3) or Virus Count (LAIV3) per Dose for Each Antigen	Recommended Dose	Thimerosal Mercury Content ^a (mcg Hg/0.5-mL dose)
Trivalent Standard Dose – Egg-Based Vaccines					
IIV3	Afluria (<i>Seqirus</i>) ^b	≥36 mo	0.5-mL prefilled syringe (15 mcg/0.5 mL)	0.5 mL	0
IIV3	Fluarix (<i>GlaxoSmithKline</i>)	≥6 mo	0.5-mL prefilled syringe (15 mcg/0.5 mL)	0.5 mL	0
IIV3	FluLaval (<i>GlaxoSmithKline</i>)	≥6 mo	0.5-mL prefilled syringe (15 mcg/0.5 mL)	0.5 mL	0
IIV3	Fluzone (<i>Sanofi Pasteur</i>)	≥6 mo 6 through 35 mo ≥36 mo	0.5-mL prefilled syringe (15 mcg/0.5 mL) 5-mL multidose vial ^{c,d} (15 mcg/0.5 mL) 5-mL multidose vial ^c (15 mcg/0.5 mL)	0.5 mL 0.25 or 0.5 mL 0.5 mL	0 25 25
Trivalent Standard Dose – Cell Culture-Based Vaccines					
ccIIV3	Flucelvax (<i>Seqirus</i>)	≥6 mo	0.5-mL prefilled syringe (15 mcg/0.5 mL)	0.5 mL	0
Recombinant Vaccine					
RIV3	Flublok (<i>Sanofi Pasteur</i>)	≥9 y	0.5-mL prefilled syringe (45 mcg/0.5 mL)	0.5 mL	0
Live Attenuated Vaccine-Egg Based Vaccine					
LAIV3	FluMist (<i>AstraZeneca</i>)	2–49 y	0.2-mL prefilled intranasal sprayer (Virus dose: 10 ^{6.5–7.5} FFU/0.2 mL)	0.2 mL (0.1 mL per nostril)	0
Abbreviations: IIV3, trivalent adjuvanted inactivated (non-live) influenza vaccine; ccIIV3, trivalent cell culture-based inactivated (non-live) influenza vaccine; FFU, fluorescent focus unit; LAIV3, trivalent live attenuated influenza vaccine; RIV3, trivalent recombinant influenza vaccine.					
^a See section on Thimerosal-Containing Vaccines.					
^b For children through 35 months, the dose of Afluria is 0.25 mL, but the manufacturer reports that neither 0.25 mL pre-filled syringes or multidose vials will be available during the 2025-2026 season.					
^c For vaccines that include a multidose vial presentation, the maximum number of doses withdrawn should not exceed the number specified in the package insert (eg, 10 doses for Fluzone). Residual product should be discarded.					
^d A total of 0.25 mL drawn from a multidose vial is an acceptable dose for children 6 to 35 months of age.					
Implementation guidance on supply, pricing, payment, billing, coding, and liability issues can be found at aap.org/influenza .					

dose administration and influenza vaccination history (Figure 1). Doses given up to 4 days prior to the minimum suggested interval are acceptable.

- When a child is recommended to receive 2 doses of vaccine in a given season, the doses do not need to be the same brand or formulation. A child may receive a combination of IIV, RIV, and LAIV if appropriate for age and health status.
- Influenza vaccine should be offered to children as soon as it becomes available, especially to those recommended to receive 2 doses. The recommended dose(s) ideally should be received by the end of October for optimal protection before the influenza season.
- For children with malignant neoplasms receiving chemotherapy, IIV or RIV should be administered ≥2 weeks before cytotoxic chemotherapy, when clinically possible.
- For children who will be starting anti-B cell therapies (eg, rituximab, alemtuzumab), IIV or RIV should optimally be provided at least 2 to 4 weeks before starting these therapies. For children who have received anti-B cell therapies, IIV should be deferred for 6 months after last dose, and ideally once there is evidence of B cell recovery.
- Non-live vaccines should be considered ≥6 months after CD19-targeted chimeric antigen receptor

(CAR)-T-cell infusion in patients who are in remission and do not require additional chemotherapy or hematopoietic cell transplantation.

- For hematopoietic cell transplant (HCT) recipients, IIV or RIV can be given starting 4 to 6 months after transplantation.
- Although high-dose IIV is not approved for use in children, clinicians could consider administering 2 doses of high-dose trivalent inactivated (non-live) influenza vaccine (IIV3) 28 to 42 days apart in pediatric HCT recipients 3 to 17 years of age.^{15,16}
- For solid organ transplant (SOT) recipients, IIV or RIV can be given starting 3 months after receipt of an SOT, although it may be considered ≥1 month after SOT during the influenza season.
- Household contacts of immunocompromised individuals should receive influenza vaccine annually.

Additional Recommendations for Pregnant and Breastfeeding Persons

- Pediatricians who interact with pregnant individuals should recommend influenza vaccination, emphasizing the benefits of vaccination for them and their infants.

TABLE 5. Influenza Vaccine Contraindications and Precautions				
Vaccine	Contraindication	Precaution	Clinician Discretion	Not Contraindication or Precaution
Egg-based inactivated (non-live) influenza vaccine (IIV) ^a	Anaphylaxis or severe allergic reaction to any previous influenza vaccination or to any vaccine component	- Moderate to severe acute illness with or without fever, including COVID-19 - History of Guillain-Barré syndrome (GBS) within 6 weeks of prior influenza vaccination		- Mild illness, with or without fever - Egg allergy
Cell culture-based inactivated (non-live) influenza vaccine (ccIIV) ^a	Anaphylaxis or severe allergic reaction to previous dose of ccIIV or any component of ccIIV	- Moderate to severe acute illness with or without fever, including COVID-19 - History of GBS within 6 weeks of prior influenza vaccination - Anaphylaxis or severe allergic reaction to any other influenza vaccine (ie, any egg-based IIV, LAIV, or RIV)		- Mild illness, with or without fever - Egg allergy
Live attenuated influenza vaccine (LAIV) ^a	- Anaphylaxis or severe allergic reaction to any previous influenza vaccination or to any vaccine component, including gelatin - Age 2–4 y with diagnosis of asthma or history of wheezing in last 12 mos - Cochlear implants - Active cerebrospinal fluid leaks - Immunosuppression due to any cause, including: - Primary or acquired immunodeficiency, including HIV - Immunosuppressive or immunomodulatory therapy - Anatomic or functional asplenia - Close contacts or caregivers of severely immunocompromised individuals - Taking aspirin or salicylate-containing medications - Receiving or recently received influenza antiviral medication^b - Currently pregnant^c	- Moderate to severe acute illness with or without fever, including COVID-19 - History of GBS within 6 weeks of prior influenza vaccination - Diagnosis of asthma and age ≥ 5 y - Certain underlying chronic conditions that might predispose to complications after influenza (eg, chronic pulmonary disease, cardiovascular disease, renal, hepatic, neurologic, hematologic, or metabolic disorders)	Defer to resolution of symptoms or use IIV if a patient has nasal congestion that could impede vaccine delivery	- Mild illness, with or without fever - Egg allergy
Recombinant HA vaccine (RIV3) ^a	Anaphylaxis or severe allergic reaction to previous dose of RIV3 or any component of RIV3	- Moderate to severe illness, with or without fever, including COVID-19 - History of GBS within 6 weeks of prior influenza vaccination - Anaphylaxis or severe allergic reaction to any other influenza vaccine (ie, any egg-based IIV, LAIV, or ccIIV)		- Mild illness, with or without fever - Egg allergy
^a Egg-based IIVs for children include Afluria, Fluarix, FluLaval, and Fluzone. Cell-culture based IIV includes Flucelvax. RIV includes Flublok. LAIV includes FluMist. ^b Within 48 hours (oseltamivir, zanamivir), 5 days (peramivir), or 17 days (baloxavir) of stopping influenza antiviral therapy. ^c Pregnancy is not a labeled contraindication for LAIV. The prescribing information for FluMist Quadrivalent, 2023–2024 formula indicated that FluMist is not absorbed systemically following intranasal administration and use during pregnancy is not expected to result in fetal exposure to the drug.				

15. Pregnant individuals may receive IIV or RIV at any time during pregnancy to protect themselves and their infants. Those who do not receive it during pregnancy should receive influenza vaccine before hospital discharge. Those who decline the vaccine during hospitalization should be encouraged to

discuss influenza vaccination with their obstetrician, family physician, nurse midwife, or other trusted clinician.

16. Influenza vaccination of a breastfeeding parent provides protection to both the parent and the infant and is recommended and safe.




FIGURE 1.

Number of 2025–2026 seasonal influenza vaccine doses recommended for children based on age and prior vaccination history.

^aMust be at least 6 months of age to be eligible for influenza vaccine.

^bSecond dose still required for children who turn 9 between first and second dose.

Additional Recommendations for Travelers

17. Individuals traveling to the tropics, on cruise ships, or to the Southern hemisphere during April to September should consider seasonal influenza vaccination ≥ 2 weeks before departure if not vaccinated during the preceding fall or winter and if vaccine is available (see section “Timing of Influenza Vaccination and Duration of Protection” in the technical report [<https://doi.org/10.1542/peds.2025-073622>]).¹⁰

Additional Recommendations for Health Care Personnel

18. The AAP supports influenza vaccination of health care personnel as a condition of employment as a crucial strategy for reducing health care-associated influenza virus infections.

Influenza Vaccine Implementation

19. Efforts should be made to promote influenza vaccination of all children, especially children younger than 5 years and those in high-risk groups (Table 2) and their contacts, unless contraindicated (Table 5), using evidence-based strategies (Table 3). To promote influenza vaccination in communities affected by health disparities, it is important to include

community members in the development of culturally relevant strategies.

20. Strategies for communicating with families about vaccines and promoting vaccine confidence are available at <https://www.aap.org/vaccinecommunication>.
21. Increasing access and reducing barriers to vaccination through schools, pharmacies, hospitals, and other nontraditional settings may improve vaccination rates. However, vaccination in the medical home is the preferred option for young children to facilitate other necessary services, including well care, preventive screening, anticipatory guidance, and other important childhood vaccinations. For patients and families for whom resource constraints would present an obstacle to receiving the vaccine in the medical home, at-home administration of LAIV is an alternative for some eligible individuals 2 through 49 years of age. Practical considerations for LAIV administered in the home setting are presented in the technical report (<https://doi.org/10.1542/peds.2025-073622>).¹⁰
22. When influenza vaccination takes place in a nontraditional setting, appropriate documentation should be provided to patients and the medical home and submitted to the state or regional immunization information systems (IISs).
23. Practices serving children and adolescents may consider offering influenza vaccine to family members and close contacts.¹⁷

Influenza Vaccine Advocacy

24. All participants in immunization efforts should work to eliminate disparities in influenza vaccine supply between privately insured patients and those eligible for vaccination through the Vaccines for Children (VFC) program.
25. Information about influenza vaccine and influenza vaccine clinics should be provided to eligible children and their families in their preferred language, especially those who may experience barriers to preventive care.
26. Public and private payers should offer adequate payment for influenza vaccine supply and administration to pediatric populations, update payments for influenza vaccine so that physicians and other clinicians who care for children are paid for administering doses in July and August and eliminate remaining “patient responsibility” cost barriers to influenza vaccination where they still exist.

INFLUENZA VACCINE CONTRAINDICATIONS AND PRECAUTIONS

Contraindications and precautions for the use of influenza vaccines are described in Table 5, and further details are provided in the technical report.¹⁰ Key points include:

1. Product-specific contraindications must be considered when selecting the type of influenza vaccine to administer.¹⁸
2. Although a history of severe allergic reaction (eg, anaphylaxis) to any influenza vaccine is generally a contraindication to future receipt of influenza vaccines, children who have had a severe allergic reaction after influenza vaccination should be evaluated by an allergist to help identify the vaccine component responsible for the reaction and to determine whether future vaccine receipt is appropriate. Children who are allergic to gelatin (very rare) should receive IIV (or RIV if age appropriate) instead of LAIV. Overlap between gelatin and alpha-gal allergy has been reported.¹⁹
3. Children with egg allergy can receive any influenza vaccine without any additional precautions beyond those recommended for all vaccines.
4. Children with acute moderate or severe illness may receive influenza vaccine as soon as their acute illness has improved; strategies to promote timely receipt once recovered from illness should be employed (ie, schedule return visit; send reminder message; if hospitalized, administer prior to discharge from hospital setting); children with mild illness, including a low-grade fever, should still be vaccinated.

INFLUENZA TESTING

Influenza Testing Recommendations Are Informed by Setting and Anticipated Impact on Clinical Management

1. Influenza testing should be performed in children with signs and symptoms of influenza when test results are anticipated to impact clinical management (eg, to inform the decision to initiate antiviral or avoid antibiotic therapy, pursue other diagnostic testing, initiate infection prevention and control measures, or distinguish from other respiratory viruses with similar symptoms). Testing for avian influenza or other novel strains should be performed at the direction of public health authorities.²⁰ Clinicians should consider asking about exposures to sick or dead animals, particularly wild birds, poultry, or dairy cows, to inform the need for testing for avian influenza.
2. When influenza is circulating in the community, hospitalized patients with signs and symptoms of influenza should be tested with a nucleic acid amplification test with high sensitivity and specificity (eg, reverse transcriptase-polymerase chain reaction [RT-PCR]).
3. At-home tests are available for children as young as 2 years of age (<https://www.fda.gov/medical-devices/in-vitro-diagnostics/influenza-diagnostic-tests>), but data on the use of these tests in pediatric patients is limited. The use of at-home test results to inform treatment decisions should be informed by the sensitivity and specificity of the test, the prevalence of influenza in

the community, the presence and duration of compatible signs and symptoms, and individual risk factors and comorbidities.

INFLUENZA TREATMENT

Antiviral medications (Table 6) are an important adjunct in the control of influenza but are not a substitute for influenza vaccination. The role of antivirals for the prevention and treatment of influenza in children depends on illness severity and risk considerations (Table 7). Options for antiviral medications along with potential benefits and harms of antiviral treatment are summarized in the technical report [<https://doi.org/10.1542/peds.2025-073622>]; see section “Rationale for Influenza Treatment in Children”.¹⁰ Although best results are observed when the child is treated within 48 hours of symptom onset, antiviral therapy should still be considered beyond 48 hours in certain cases.

1. Physicians and other clinicians who care for children should promptly identify patients suspected of having influenza for timely initiation of antiviral treatment, when indicated, to reduce morbidity and mortality. Treatment of children who are not at high risk for influenza complications in the outpatient setting should be based on shared decision making between the clinician and child’s parent/guardian.
2. Provision of antiviral therapy does not require a positive test for influenza when influenza is circulating in the community. Initiation of antiviral therapy should be based on signs and symptoms consistent with influenza infection, patient risk factors, and epidemiologic factors (eg, influenza circulating in the community, known exposure, etc).
3. The AAP considers oseltamivir the preferred antiviral medication for patients with influenza A and B because of the cumulative experience of this drug in children, relative cost, and ease of administration. Clinicians should refer to the CDC (https://www.cdc.gov/flu/hcp/antivirals/summary-clinicians.html#cdc_generic_section_9-influenza-antiviral-resistance-considerations; recommendations for the use of oseltamivir differ from FDA-approved labeling) for the most up-to-date information on antiviral susceptibilities.

Recommendations for Treatment and Chemoprophylaxis of Specific Populations

4. Antiviral treatment should be offered as early as possible to the following individuals, regardless of influenza vaccination status and duration of symptoms¹:
 - Any child hospitalized with suspected or confirmed influenza disease.
 - Any child with severe, complicated, or progressive influenza disease, regardless of health care setting (ie, inpatient or outpatient).

TABLE 6. Recommended Dosage and Schedule of Influenza Antiviral Medications for Treatment and Chemoprophylaxis in Children for the 2025–2026 Influenza Season: United States

Medication	Treatment		Chemoprophylaxis		Common Adverse Events ^a
	Dosage	Duration	Dosage	Duration After Last Exposure	
Oseltamivir ^{b,c}					
Adults	75 mg, twice daily, orally or by feeding tube	5 d	75 mg, once daily	7 d	
Children ≥12 mo					
≤15 kg	30 mg, twice daily, orally or by feeding tube	5 d	30 mg, once daily	7 d	Nausea Vomiting Headache
>15 kg–23 kg	45 mg, twice daily, orally or by feeding tube	5 d	45 mg, once daily	7 d	
>23 kg–40 kg	60 mg, twice daily, orally or by feeding tube	5 d	60 mg, once daily	7 d	
>40 kg	75 mg, twice daily, orally or by feeding tube	5 d	75 mg, once daily	7 d	
Infants 9–11 mo ^d	3.5 mg/kg per dose, twice daily, orally or by feeding tube	5 d	3.5 mg/kg per dose, once daily	7 d	Skin reactions Diarrhea (children <1 y of age)
Term infants 0–8 mo ^d	3 mg/kg per dose, twice daily, orally or by feeding tube	5 d	3–8 mo: 3 mg/kg per dose, once daily	7 d	
Preterm infants ^e					
<38 weeks' PMA	1 mg/kg per dose, twice daily, orally or by feeding tube	5 d	See footnote		
38–40 weeks' PMA	1.5 mg/kg per dose, twice daily, orally or by feeding tube	5 d			
>40 weeks' PMA	3 mg/kg per dose, twice daily, orally or by feeding tube	5 d			
Zanamivir ^{c,f}					
Adults	10 mg (two 5-mg inhalations), twice daily	5 d	10 mg (two 5-mg inhalations), once daily	7 d ^c	Bronchospasm Skin reactions Sinusitis Dizziness
Children	≥7 y: 10 mg (two 5-mg inhalations), twice daily	5 d	≥5 y: 10 mg (two 5-mg inhalations), once daily	7 d ^b	
Peramivir ^g					
Adults	One 600-mg dose via intravenous infusion, given over 15–30 min	N/A	Not recommended		Diarrhea Skin reactions
Children 6 mos–12 y	One 12-mg/kg dose (600 mg maximum) via intravenous infusion over 15–30 min	N/A	Not recommended		
13–17 y	One 600-mg dose, via intravenous infusion over 15–30 min	N/A	Not recommended		
Baloxavir ^h					
Individuals ≥5 y					
<20 kg	One 2-mg/kg dose, orally or by feeding tube	N/A	2 mg/kg as single dose, orally	N/A	Adverse events reported in clinical trials, including nausea, vomiting, and diarrhea, similar to placebo
20 kg–<80 kg	One 40-mg dose, orally or by feeding tube	N/A	One 40-mg dose	N/A	
≥80 kg	One 80-mg dose, orally or by feeding tube	N/A	One 80-mg dose, orally	N/A	

^a Although only common adverse events are listed in this table, hypersensitivity reactions, including anaphylaxis, have been reported postmarketing with oseltamivir and baloxavir. Hypersensitivity reactions have also been reported with peramivir and zanamivir.

^b Oseltamivir is administered orally or by feeding tube without regard to meals, although administration with meals may improve gastrointestinal tolerability. Oseltamivir is available as a generic drug or as Tamiflu in 30-mg, 45-mg, and 75-mg capsules and as a powder for oral suspension that is reconstituted to provide a final concentration of 6 mg/mL. For the 6-mg/mL suspension, a 30-mg dose is given with 5 mL of oral suspension, a 45-mg dose is given with 7.5 mL oral suspension, a 60-mg dose is given with 10 mL oral suspension, and a 75-mg dose is given with 12.5 mL oral suspension. If the commercially manufactured oral suspension is not available, a suspension can be compounded by retail pharmacies (final concentration also 6 mg/mL), based on instructions contained in the package label. For infants younger than 1 year, an appropriate measuring device such as a 3-mL or 5-mL oral syringe should be used to measure the dose instead of the syringe supplied.

In patients with renal insufficiency, the dose should be adjusted on the basis of creatinine clearance. Renal dosing of oseltamivir is not available in the package insert for pediatric patients. However, the package insert instructions may be useful for children who qualify for adult doses based on weight >40 kg. For treatment of patients with creatinine clearance 10–30 mL/min: 75 mg, once daily, for 5 days. For chemoprophylaxis of patients with creatinine clearance 10–30 mL/min: 30 mg, once daily, for 10 days after exposure or 75 mg, once every other day, for 10 days after exposure (5 doses).

(Continued on next page)

TABLE 6. Recommended Dosage and Schedule of Influenza Antiviral Medications for Treatment and Chemoprophylaxis in Children for the 2025–2026 Influenza Season: United States (Continued)

^c The Centers for Disease Control and Prevention (CDC) recommends routine chemoprophylaxis with oseltamivir or zanamivir for 7 days after last known exposure; minimum of 14 days and continuing for 7 days after last known exposure if part of institutional outbreak (https://www.cdc.gov/flu/hcp/antivirals/summary-clinicians.html). This differs from the package insert for zanamivir, which recommends prophylaxis for 10 days in community settings and 28 days in community outbreaks (https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021036s025ibl.pdf). ^d Approved by the US Food and Drug Administration (FDA) for treatment of children as young as 2 weeks of age. Given preliminary pharmacokinetic data and limited safety data, oseltamivir can be used to treat influenza in both term and preterm infants from birth because benefits of therapy are likely to outweigh possible risks of treatment. Oseltamivir is not FDA-approved for postexposure prophylaxis (PEP) in children younger than 1 year. Oseltamivir is not recommended by the American Academy of Pediatrics (AAP) or CDC for chemoprophylaxis of infants <3 months because of limited safety and efficacy data in this age group. Of note, the dose recommended by the AAP for treatment of infants 9 to 11 months of age is higher than the FDA approved dose of 3.0 mg/kg, twice daily and is based on data that indicated that the higher dose was needed to achieve the protocol-defined targeted exposure for infants in this age group as defined in the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group 114 study.²⁷ The CDC recommends a dose of 3.0 mg/kg, twice daily, for all infants <12 months; the IDSA guidelines²⁶ include both AAP and CDC recommendations. ^e Oseltamivir dosing for preterm infants. The weight-based dosing recommendation for preterm infants is lower than for term infants.^{28–30} Preterm infants may have lower clearance of oseltamivir because of immature renal function, and doses recommended for full-term infants may lead to very high drug concentrations in this age group. Limited data from the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group provide the basis for dosing preterm infants using their postmenstrual age (PMA) (gestational age + chronologic age). For extremely preterm infants (<28 weeks), please consult a pediatric infectious disease physician. PEP is not generally recommended for preterm infants because of limited data on use in these infants unless PEP is determined to be essential for outbreak control based on clinician judgment. Optimal dosing has not been defined in this circumstance. ^f Zanamivir is administered by inhalation using a proprietary “Diskhaler” device distributed together with the medication. Zanamivir is a dry powder, not an aerosol, and should not be administered using nebulizers, ventilators, or other devices typically used for administering medications in aerosolized solutions. Zanamivir is not recommended for people with chronic respiratory diseases, such as asthma or chronic obstructive pulmonary disease, which increase the risk of bronchospasm. ^g Peramivir requires dose adjustment in patients with renal insufficiency. For treatment of pediatric patients 6 months to 12 years of age: 2 mg/kg if creatinine clearance is 10–29 mL/min; 4 mg/kg if creatinine clearance is 30 to 49 mL/min. For treatment of adolescents 13 years and older: 100 mg if creatinine is clearance 10–29 mL/min; 200 mg if creatinine clearance is 30 to 49 mL/min (https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/206426s004ibl.pdf). ^h Oral baloxavir marboxil is approved by the FDA for treatment of acute uncomplicated influenza within 2 days of illness onset. It should not be administered with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements (eg, calcium, iron, magnesium, selenium, or zinc). Baloxavir marboxil is not recommended as monotherapy for treatment of influenza in individuals who are severely immunocompromised. It is not recommended for persons who are pregnant or breastfeeding. Sources: IDSA²⁶ and https://www.cdc.gov/flu/hcp/antivirals/summary-clinicians.html?CDC_ARef_Val=https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm.
--

- Any child with suspected or confirmed influenza disease of any severity if they are younger than 5 years or they belong to other high-risk groups for influenza complications, regardless of health care setting (ie, inpatient or outpatient) (Table 2).
- 5. Treatment is an option for the following individuals in the outpatient setting:
 - Any child with suspected or confirmed influenza disease who is not at high risk for influenza complications, if treatment can be initiated within 48 hours of illness onset.
 - Any child with suspected or confirmed influenza disease whose siblings or household contacts are either younger than 6 months or at high risk for influenza complications (Table 2).

INFLUENZA CHEMOPROPHYLAXIS RECOMMENDATIONS

1. Chemoprophylaxis is not a substitute for vaccination, and among some high-risk people, both vaccination with IIV or RIV and antiviral chemoprophylaxis is an option.
2. The AAP considers oseltamivir to be the preferred postexposure chemoprophylaxis for influenza A and/or B.
3. Postexposure chemoprophylaxis should only be used when antiviral agents can be initiated within 48 hours of exposure.
4. Postexposure chemoprophylaxis should not be used for routine or widespread prophylaxis outside of institutional outbreaks. Postexposure chemoprophylaxis is

recommended for unvaccinated staff and unvaccinated children in a closed institutional setting with children at high risk for influenza complications (eg, extended-care facilities) to control influenza outbreaks.

5. Postexposure chemoprophylaxis can be considered after known or suspected influenza exposure for children in the following situations:
 - Any child at high risk for influenza complications if:
 - They cannot receive the influenza vaccine.
 - They have not yet been administered influenza vaccination this season.
 - They received influenza vaccine in the past 2 weeks or may not have mounted a sufficient response because of immunosuppression (ie, suboptimal immunity).
 - Influenza virus strains circulating in the community are not well-matched with those of the seasonal influenza vaccine.
 - Any unvaccinated child with a family member or close contact who is at high risk for influenza complications and is unable to be otherwise effectively protected from influenza.
6. Postexposure chemoprophylaxis can be considered for known or suspected influenza exposed family members or close contacts of children at high risk for influenza complication in the following situations:
 - Unvaccinated family members and close contacts who are likely to have ongoing, close exposure to unvaccinated children at high risk for influenza complications or unvaccinated children who are younger than 24 months.

TABLE 7. Summary of Antiviral Treatment and Chemoprophylaxis Recommendations			
Applicable Subpopulation	Who Would Receive Antiviral Medications	Time Since Symptoms or Exposure	Medication Plan
Hospitalized children	Child with symptoms and known or suspected infection ^a	No time limit on starting although treatment should ideally be started as soon as possible after symptom onset	Recommend treatment
Children with severe illness	Child with symptoms and known or suspected infection ^a	No time limit on starting	Recommend treatment
Children with complicated illness	Child with symptoms and known or suspected infection ^a	No time limit on starting	Recommend treatment
Children with progressive illness	Child with symptoms and known or suspected infection ^a	No time limit on starting	Recommend treatment
Children at higher risk for complications (<5 y of age or with underlying condition [Table 2])	Child with symptoms and known or suspected infection ^a	No time limit on starting	Recommend treatment
Children with household contacts at high risk	Child with symptoms and known or suspected infection ^a	No time limit on starting	Consider treatment
Children with household contacts under age 6 mos	Child with symptoms and known or suspected infection ^a	No time limit on starting	Consider treatment
Other children with flu-like symptoms	Child with symptoms and known or suspected infection ^a	Within 48 h of symptoms starting	Consider treatment
Unvaccinated or incompletely vaccinated children at high risk of complications	Asymptomatic child with known or suspected exposure	Within 48 h of exposure	Consider chemoprophylaxis
Vaccinated children at high risk of complications who may have not mounted an immune response	Asymptomatic child with known or suspected exposure	Within 48 h of exposure	Consider chemoprophylaxis
Vaccinated children at high risk of complications when vaccination strain does not match or is ineffective against circulating strains	Asymptomatic child with known or suspected exposure	Within 48 h of exposure	Consider chemoprophylaxis
Unvaccinated children with a family member or close contact who is at high risk for influenza complications and is unable to be otherwise effectively protected from influenza	Asymptomatic child with known or suspected exposure	Within 48 h of exposure	Consider chemoprophylaxis
Unvaccinated family members and close contacts of unvaccinated children at high risk of complications or unvaccinated children under 24 mos old	Asymptomatic close contact with known or suspected exposure	Within 48 h of exposure	Consider chemoprophylaxis
Family members and close contacts of children at high risk of complications when vaccination strain does not match or is ineffective against circulating strains	Asymptomatic close contact with known or suspected exposure	Within 48 h of exposure	Consider chemoprophylaxis

^a Once testing results are available, treatment could be tailored accordingly.

- Influenza virus strains circulating in the community are not well matched with those of the seasonal influenza vaccine, per the CDC.

COMMITTEE ON INFECTIOUS DISEASES, 2024–2025

Sean T. O'Leary, MD, MPH, FAAP, Chairperson
 James D. Campbell, MD, MS, FAAP, Vice Chairperson
 Monica I. Ardura, DO, MSCS, FAAP
 Kristina A. Bryant, MD, FAAP, *Red Book Online* Team Lead
 Mary T. Caserta, MD, FAAP

Claudia Espinosa, MD, MSc, FAAP
 Robert W. Frenck, Jr, MD, FAAP
 C. Mary Healy, MD
 Chandy C. John, MD, MS, FAAP
 Aaron M. Milstone, MD, MHS, FAAP
 Angela L. Myers, MD, MPH, FAAP
 Pia Pannaraj, MD, MPH, FAAP
 Adam J. Ratner, MD, MPH, FAAP, *Red Book* Associate Editor
 José R. Romero, MD, FAAP
 Matthew Zahn, MD, FAAP

CONTRIBUTORS

Kristina A. Bryant, MD, FAAP
Annika M. Hofstetter, MD, PhD, MPH, FAAP

PARTNERSHIP FOR POLICY IMPLEMENTATION

Juan D. Chaparro, MD, MS, FAAP
Jeremy J. Michel, MD, MHS, FAAP

EX OFFICIO

David W. Kimberlin, MD, FAAP, *Red Book* Editor
Ritu Banerjee, MD, PhD, FAAP, *Red Book* Associate Editor
Elizabeth D. Barnett MD, FAAP, *Red Book* Associate Editor
Ruth Lynfield, MD, FAAP, *Red Book* Associate Editor

LIAISONS

Amina Ahmed, MD, FAAP, American Thoracic Society
Michelle Barton, MD, Canadian Paediatric Society
Lisa M. Kafer, MD, FAAP, AAP Committee on Practice and Ambulatory Medicine
Denée J. Moore, MD, American Academy of Family Physicians
Jennifer L. Thompson, MD, American College of Obstetricians and Gynecologists
Juan P. Torres, MD, PhD, Sociedad Latinoamericana de Infectología Pediátrica
Charles R. Woods, Jr, MD, MS, FAAP, Pediatric Infectious Diseases Society

STAFF

Gillian Gibbs, MPH

ACKNOWLEDGMENTS

The Committee on Infectious Diseases gratefully acknowledges Kristina A. Bryant, MD, FAAP, and Annika M. Hofstetter, MD, PhD, MPH, FAAP, for their leadership in drafting the policy statement and technical report, and Juan D. Chaparro, MD, MS, FAAP, and Jeremy J. Michel, MD, MHS, FAAP, for their significant contributions in providing input on the initial drafts on behalf of the AAP Partnership for Policy Implementation.

ABBREVIATIONS

AAP: American Academy of Pediatrics
FDA: US Food and Drug Administration
ccIV: cell culture-based inactivated (non-live) influenza vaccine
ccIV3: trivalent cell culture-based inactivated (non-live) influenza vaccine
IIV: inactivated (non-live) influenza vaccine
IIV3: trivalent inactivated (non-live) influenza vaccine
LAIV: live attenuated influenza vaccine
LAIV3: trivalent live attenuated influenza vaccine
RIV: recombinant influenza vaccine
RIV3: trivalent recombinant influenza vaccine
WHO: World Health Organization

All policy statements from the American Academy of Pediatrics automatically expire 5 years after publication unless reaffirmed, revised, or retired at or before that time.

Embedded links to cdc.gov and fda.gov sites were active and reviewed by AAP subject matter experts as of July 5, 2025.

<https://doi.org/10.1542/peds.2025-073620>

COMPANION PAPER: A companion to this article can be found online at www.pediatrics.org/cgi/doi/10.1542/peds.2025-073622.

Copyright © 2025 by the American Academy of Pediatrics

REFERENCES

1. Grohskopf LA, Ferdinands JM, Blanton LH, Broder KR, Loehr J. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2024–25 influenza season. *MMWR Recomm Rep*. 2024;73(RR-5):1–25. doi: 10.15585/mmwr.rr7305a1
2. White EB, O'Halloran A, Sundaresan D, et al. High influenza incidence and disease severity among children and adolescents aged <18 years—United States, 2022–23 season. *MMWR Morb Mortal Wkly Rep*. 2023;72(41):1108–1114. PubMed doi: 10.15585/mmwr.mm7241a2
3. Hauge SH, de Blasio BF, Håberg SE, Oakley L. Influenza hospitalizations during childhood in children born preterm. *Influenza Other Respir Viruses*. 2022;16(2):247–254. PubMed doi: 10.1111/irv.12908
4. Neuzil KM, Hohlbein C, Zhu Y. Illness among schoolchildren during influenza season: effect on school absenteeism, parental absenteeism from work, and secondary illness in families. *Arch Pediatr Adolesc Med*. 2002;156(10):986–991. PubMed doi: 10.1001/archpedi.156.10.986
5. Shope TR, Walker BH, Aird LD, Southward L, McCown JS, Martin JM. Pandemic influenza preparedness among child care center

- directors in 2008 and 2016. *Pediatrics*. 2017;139(6):e20163690. PubMed doi: 10.1542/peds.2016-3690
6. Petrie JG, Ohmit SE, Cowling BJ, et al. Influenza transmission in a cohort of households with children: 2010–2011. *PLoS One*. 2013; 8(9):e75339. PubMed doi: 10.1371/journal.pone.0075339
7. Loeb M, Russell ML, Moss L, et al. Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. *JAMA*. 2010;303(10):943–950. PubMed doi: 10.1001/jama.2010.250
8. Pannaraj PS, Wang HL, Rivas H, et al. School-located influenza vaccination decreases laboratory-confirmed influenza and improves school attendance. *Clin Infect Dis*. 2014;59(3):325–332. PubMed doi: 10.1093/cid/ciu340
9. Centers for Disease Control and Prevention. Weekly Flu Vaccination Dashboard: Influenza Vaccination Coverage, Children 6 months through 17 years, United States. Accessed August 3, 2025. <https://www.cdc.gov/fluview/dashboard/children-vaccination-coverage.html>
10. American Academy of Pediatrics, Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2025–2026: Technical report. *Pediatrics*. 2025; 156(4):e2025073622. doi: 10.1542/peds.2025-073622
11. US Food and Drug Administration. Flublok package insert. Accessed March 25, 2025. <https://www.fda.gov/media/179778/download>
12. O'Halloran AC, Holstein R, Cummings C, et al. Rates of influenza-associated hospitalization, intensive care unit admission, and in-hospital death by race and ethnicity in the United States from 2009 to 2019. *JAMA Netw Open*. 2021;4(8):e2121880. PubMed doi: 10.1001/jamanetworkopen.2021.21880
13. World Health Organization. Recommendations announced for influenza vaccine composition for the 2025–2026 northern hemisphere influenza season. Accessed March 25, 2025. <https://www.who.int/news/item/28-02-2025-recommendations-announced-for-influenza-vaccine-composition-for-the-2025-2026-northern-hemisphere-influenza-season>
14. US Food and Drug Administration. Influenza Vaccine Composition for the 2025–2026 U.S. Influenza Season. Accessed March 25, 2025. <https://www.fda.gov/vaccines-blood-biologics/influenza-vaccine-composition-2025-2026-us-influenza-season>
15. Schuster JE, Hamdan L, Dulek DE, et al; Pediatric HCT Flu Study Group. Influenza vaccine in pediatric recipients of hematopoietic-cell transplants. *N Engl J Med*. 2023;388(4):374–376. PubMed doi: 10.1056/NEJMc2210825
16. Schuster JE, Hamdan L, Dulek DE, et al; Pediatric HCT Flu Study. Pediatric HCT Flu Study. The durability of antibody responses of two doses of high-dose relative to two doses of standard-dose inactivated influenza vaccine in pediatric hematopoietic cell transplant recipients: a multi-center randomized controlled trial. *Clin Infect Dis*. 2024;78(1):217–226. PubMed doi: 10.1093/cid/ciad534
17. Lessin HR, Edwards KM; American Academy of Pediatrics, Committee on Practice and Ambulatory Medicine, Committee on Infectious Diseases. Immunizing parents and other close family contacts in the pediatric office setting. *Pediatrics*. 2012; 129(1):e247–e253. PubMed doi: 10.1542/peds.2011-2937
18. US Food and Drug Administration. Vaccines licensed for use in the United States. Accessed May 25, 2025. <https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states>
19. Moschese V, Montin D, Ottaviano G, et al; within the Italian Society of Pediatric Allergology and Immunology (SIAIP) Vaccine Committee. Vaccines and allergy: Back to the right places. *Pediatr Allergy Immunol*. 2024;35(9):e14236. PubMed doi: 10.1111/pai.14236
20. Centers for Disease Control and Prevention. Avian Influenza (Bird Flu). Laboratory and Testing Information for Novel Influenza A Viruses. Accessed May 25, 2025. <https://www.cdc.gov/bird-flu/php/severe-potential/index.html>
21. Homaira N, Briggs N, Oei JL, et al. Impact of influenza on hospitalization rates in children with a range of chronic lung diseases. *Influenza Other Respir Viruses*. 2019;13(3):233–239. PubMed doi: 10.1111/irv.12633
22. Schütte A, Ciesek S, Wedemeyer H, Lange CM. Influenza virus infection as precipitating event of acute-on-chronic liver failure. *J Hepatol*. 2019;70(4):797–799. PubMed doi: 10.1016/j.jhep.2018.11.015
23. Premkumar M, Devurgowda D, Dudha S, et al. A/H1N1/09 influenza is associated with high mortality in liver cirrhosis. *J Clin Exp Hepatol*. 2019;9(2):162–170. PubMed doi: 10.1016/j.jceh.2018.04.006
24. Hampf SE, Hassink SG, Skinner AC, et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. *Pediatrics*. 2023;151(2):e2022060640. PubMed doi: 10.1542/peds.2022-060640
25. Vitoratou D-I, Milas G-P, Korovessi P, Kostaridou S, Koletsis P. Obesity as a risk factor for severe influenza infection in children and adolescents: a systematic review and meta-analysis. *Eur J Pediatr*. 2023;182(1):363–374. PubMed doi: 10.1007/s00431-022-04689-0
26. Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical practice guidelines by the Infectious Diseases Society of America (IDSA): 2018 Update diagnosis, treatment, chemoprophylaxis and institutional outbreak management of seasonal influenza. *Clin Infect Dis*. 2019; 68(6):e1–e47. PubMed doi: 10.1093/cid/ciy866
27. Kimberlin DW, Acosta EP, Prichard MN, et al; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenza. *J Infect Dis*. 2013;207(5):709–720. PubMed doi: 10.1093/infdis/jis765
28. Pannaraj PS, Tam B, Akan D. Oseltamivir treatment and prophylaxis in a neonatal intensive care unit during a 2009 H1N1 influenza outbreak. *J Perinatol*. 2011;31(7):487–493. PubMed doi: 10.1038/jp.2010.159
29. Acosta EP, Jester P, Gal P, et al; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Oseltamivir dosing for influenza infection in premature neonates. *J Infect Dis*. 2010;202(4):563–566. PubMed doi: 10.1086/654930
30. McPherson C, Warner B, Hunstad DA, Elward A, Acosta EP. Oseltamivir dosing in premature infants. *J Infect Dis*. 2012; 206(6):847–850. PubMed doi: 10.1093/infdis/jis471